The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Induction of p21WAF1/CIP1/SDI1 in kidney tubule cells affects the course of cisplatin-induced acute renal failure.
Open accessAbstract
The p21 protein is found in the nucleus of most cells at low levels and is induced to elevated levels after DNA damage, causing cell-cycle arrest. We have reported that p21 mRNA is rapidly induced to high levels in murine kidney after acute renal failure. The function(s) in the kidney of p21 induction in cisplatin-induced acute renal failure was studied with mice that are homozygous for a p21 gene deletion. After drug administration, as compared with their wild-type littermates, p21(-/-) mice display a more rapid onset of the physiologic signs of acute renal failure, develop more severe morphologic damage, and have a higher mortality. Therefore, the induction of p21 after cisplatin administration is a protective event for kidney cells. Using both bromodeoxyuridine incorporation and nuclear proliferating cell nuclear antigen detection, we found that cisplatin administration caused kidney cells to start entering the cell-cycle. However, cell-cycle progression is inhibited in wild-type mice, whereas kidney cells in the p21(-/-) mice progress into S-phase. We propose that p21 protects kidneys damaged by cisplatin by preventing DNA-damaged cells from entering the cell-cycle, which would otherwise result in death from either apoptosis or necrosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation.
Gavrieli, Y., Sherman, Y., & Ben-Sasson, S. A. (1992) · The Journal of cell biology · doi:10.1083/jcb.119.3.493 · Cited by 9,444
WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases.
Wade Harper, J. (1993) · Cell · doi:10.1016/0092-8674(93)90499-g · Cited by 5,651
The p53 tumour suppressor gene
Levine, A. J., Momand, J., & Finlay, C. A. (1991) · Nature · doi:10.1038/351453a0 · Cited by 3,788
Participation of p53 protein in the cellular response to DNA damage.
Kastan, M. B., Onyekwere, O. C., Sidransky, D., Vogelstein, B., & Craig, R. W. (1991) · PubMed · Cited by 3,761
p21 is a universal inhibitor of cyclin kinases
Xiong, Y., Hannon, G. J., Zhang, H., Casso, D., Kobayashi, R., & Beach, D. (1993) · Nature · doi:10.1038/366701a0 · Cited by 3,368
WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis.
El‐Deiry, W. S., Harper, J. W., O'Connor, P. M., Velculescu, V. E., Ce, C., Jackman, J., Pietenpol, J. A., Burrell, M., De, H., & Wang, Y. (1994) · PubMed · Cited by 2,336
Mice Lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control
Deng, C., Zhang, P., Wade Harper, J., Elledge, S. J., & Leder, P. (1995) · Cell · doi:10.1016/0092-8674(95)90039-x · Cited by 2,113
Polyak, K., Kato, J. Y., Solomon, M. J., Sherr, C. J., Massague, J., Roberts, J. M., & Koff, A. (1994) · Genes & Development · doi:10.1101/gad.8.1.9 · Cited by 1,954
The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA
Waga, S., Hannon, G. J., Beach, D., & Stillman, B. (1994) · Nature · doi:10.1038/369574a0 · Cited by 1,655
Cited by
Cisplatin nephrotoxicity: Mechanisms and renoprotective strategies
Pabla, N., & Dong, Z. (2008) · Kidney International · doi:10.1038/sj.ki.5002786 · Cited by 1,918
Mishra, J., Ma, Q., Prada, A., Mitsnefes, M., Zahedi, K., Yang, J., Barasch, J., & Devarajan, P. (2003) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000088027.54400.c6 · Cited by 1,749
Mechanisms of Cisplatin Nephrotoxicity
Miller, R. P., Tadagavadi, R. K., Ramesh, G., & Reeves, W. B. (2010) · Toxins · doi:10.3390/toxins2112490 · Cited by 1,622
Pathophysiology of Acute Kidney Injury
Basile, D. P., Anderson, M. D., & Sutton, T. A. (2012) · Comprehensive Physiology · doi:10.1002/cphy.c110041 · Cited by 1,094
Arany, I., & Safirstein, R. L. (2003) · Seminars in Nephrology · doi:10.1016/s0270-9295(03)00089-5 · Cited by 906
Self-citationTNF-α mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity
Ramesh, G., & Reeves, W. B. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15606 · Cited by 866
Pathophysiology of Cisplatin-Induced Acute Kidney Injury
Ozkok, A., & Edelstein, C. L. (2014) · BioMed Research International · doi:10.1155/2014/967826 · Cited by 703
Cisplatin nephrotoxicity: new insights and therapeutic implications
Tang, C., Livingston, M. J., Safirstein, R., & Dong, Z. (2023) · Nature Reviews Nephrology · doi:10.1038/s41581-022-00631-7 · Cited by 548
Self-citationDifferent Faces of the Heme-Heme Oxygenase System in Inflammation
Wagener, F. A. D. T. G., Volk, H.-D., Willis, D., Abraham, N. G., Soares, M. P., Adema, G. J., & Figdor, C. G. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.3.5 · Cited by 537
Mishra, J., Mori, K., Ma, Q., Kelly, C., Barasch, J., & Devarajan, P. (2004) · American Journal of Nephrology · doi:10.1159/000078452 · Cited by 535
Cisplatin: a review of toxicities and therapeutic applications
Barabas, K., Milner, R., Lurie, D., & Adin, C. (2008) · Veterinary and Comparative Oncology · doi:10.1111/j.1476-5829.2007.00142.x · Cited by 446
Advances in Toxicological Research of the Anticancer Drug Cisplatin
Qi, L., Luo, Q., Zhang, Y., Jia, F., Zhao, Y., & Wang, F. (2019) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.9b00204 · Cited by 440
Reactive oxygen species and acute renal failure
Nath, K. A., & Norby, S. M. (2000) · The American Journal of Medicine · doi:10.1016/s0002-9343(00)00612-4 · Cited by 429
Biomarkers in acute kidney injury – pathophysiological basis and clinical performance
Schrezenmeier, E. V., Barasch, J., Budde, K., Westhoff, T., & Schmidt‐Ott, K. M. (2017) · Acta Physiologica · doi:10.1111/apha.12764 · Cited by 401
Interleukin-10 inhibits ischemic and cisplatin-induced acute renal injury
Deng, J., Kohda, Y., Chiao, H., Wang, Y., Hu, X., Hewitt, S. M., Miyaji, T., Mcleroy, P., Nibhanupudy, B., Li, S., et al. (2001) · Kidney International · doi:10.1046/j.1523-1755.2001.00043.x · Cited by 399
Contribution of Organic Cation Transporter 2 (OCT2) to Cisplatin-Induced Nephrotoxicity
Filipski, K. K., Mathijssen, R. H., Mikkelsen, T. S., Schinkel, A. H., & Sparreboom, A. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.139 · Cited by 399
Cellular senescence in renal ageing and disease
Sturmlechner, I., Durik, M., Sieben, C. J., Baker, D. J., & van Deursen, J. M. (2017) · Nature Reviews Nephrology · doi:10.1038/nrneph.2016.183 · Cited by 345
Heme oxygenase-1 gene ablation or expression modulates cisplatin-induced renal tubular apoptosis
Shiraishi, F., Curtis, L. M., Truong, L., Poss, K., Visner, G. A., Madsen, K., Nick, H. S., & Agarwal, A. (2000) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.2000.278.5.f726 · Cited by 315
Zhang, B., Ramesh, G., Norbury, C. C., & Reeves, W. B. (2007) · Kidney International · doi:10.1038/sj.ki.5002242 · Cited by 309
Biomarkers of acute kidney injury: the pathway from discovery to clinical adoption
Kashani, K., Cheungpasitporn, W., & Ronco, C. (2017) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2016-0973 · Cited by 289
Cisplatin Induces Apoptosis in LLC-PK1 Cells via Activation of Mitochondrial Pathways
Park, M. S., De Leon, M., & Devarajan, P. (2002) · Journal of the American Society of Nephrology · doi:10.1681/asn.v134858 · Cited by 279
p38 MAP kinase inhibition ameliorates cisplatin nephrotoxicity in mice
Ramesh, G., & Reeves, W. B. (2005) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00401.2004 · Cited by 267
Cisplatin-Associated Nephrotoxicity and Pathological Events
Taguchi, T., Nazneen, A., Abid, M. R., & Razzaque, M. S. (2005) · Contributions to Nephrology · doi:10.1159/000086055 · Cited by 256
Positive effect of the induction of p21WAF1/CIP1 on the course of ischemic acute renal failure
Megyesi, J., Andrade, L., Vieira, J. M., Safirstein, R. L., & Price, P. M. (2001) · Kidney International · doi:10.1046/j.1523-1755.2001.00044.x · Cited by 153
Self-citationCyclin G1 and TASCC regulate kidney epithelial cell G 2 -M arrest and fibrotic maladaptive repair
Canaud, G., Brooks, C. R., Kishi, S., Taguchi, K., Nishimura, K., Magassa, S., Scott, A., Hsiao, L.-L., Ichimura, T., Terzi, F., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aav4754 · Cited by 139
Pathophysiological role of different tubular epithelial cell death modes in acute kidney injury
Sancho-Martínez, S. M., López-Novoa, J. M., & López-Hernández, F. J. (2015) · Clinical Kidney Journal · doi:10.1093/ckj/sfv069 · Cited by 130
Proximal tubule ATR regulates DNA repair to prevent maladaptive renal injury responses
Kishi, S., Brooks, C. R., Taguchi, K., Ichimura, T., Mori, Y., Akinfolarin, A., Gupta, N., Galichon, P., Elias, B. C., Suzuki, T., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci122313 · Cited by 117
Nutlin-3 protects kidney cells during cisplatin therapy by suppressing Bax/Bak activation
Jiang, M., Pabla, N., Murphy, R. F., Yang, T., Yin, X.-M., Degenhardt, K., White, E., & Dong, Z. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m606928200 · Cited by 97
Battaglia-Vieni, A., Marchant, V., Tejedor-Santamaria, L., García-Caballero, C., Flores-Salguero, E., Ruiz-Torres, M. P., Rayego-Mateos, S., Sanz, A. B., Ortiz, A., & Ruiz-Ortega, M. (2025) · Pharmaceuticals · doi:10.3390/ph18060822 · Cited by 6
Metadata
- Authors
- Megyesi, J., Safirstein, R. L., & Price, P. M.
- Venue
- Journal of Clinical Investigation
- Published
- 1998-02-15
- Volume
- 101
- Issue
- 4
- Pages
- 777-782
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2019316722
- Cited by
- 272
- References
- 47
- FWCI
- 5.87
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.